ClinicalTrials.gg
CompletedNCT03890731Updated Apr 2, 2024Results posted

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

A Phase 2 interventional study of BAY73-4506 (Regorafenib, Stivarga) in Solid Cancer, sponsored by Bayer. Completed at 6 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing regorafenib in Colorectal Neoplasms — 10 open to participants now, 15 under way, 3 of them phase 3. regorafenib · Colorectal Neoplasms.

Enrollment
54th of 58
6 · median 55
Started
2019
with 6 others
Phase 2
29 of 59
5 open now
Registered
36th of 59
by date
Lead sponsor
10 of 59
Bayer

Among the 59 studies testing regorafenib in Colorectal Neoplasms, this one is the 54th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2019, is one of 29 in phase 2, and was the 36th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

10 of the 59 studies testing regorafenib in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing regorafenib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. Patients participating in this study will be observed to collect information on how safe the drugs are and how this treatment is tolerated.

Read the detailed description

The primary objectives of the study are a) to allow patients from Bayer-sponsored trials to continue regorafenib treatment after their respective study has been completed, and b) to further assess the safety of regorafenib. Secondary objective is the documentation of drug tolerability.

03

Conditions studied

  • Solid Cancer

Keywords

  • Metastatic colorectal cancer (mCRC)
  • Renal cell cancer
  • Gastro-intestinal stromal tumor
  • Hepatocellular carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be age-eligible in the feeder study at the time of signing the .
  • Participant is currently participating in any Bayer-sponsored regorafenib study and is receiving study treatment.
  • Participant is currently benefiting from treatment with regorafenib monotherapy and meets criteria to initiate a subsequent cycle of therapy, as determined by the guidelines of the feeder protocol.
  • Any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Medical reasons not to start the next treatment cycle in the respective feeder
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Other
    Adult patients

    Adult patients from completed Bayer-sponsored regorafenib trials who are benefitting from regorafenib treatment.

    Drug: BAY73-4506 (Regorafenib, Stivarga)

Interventions

  • Regorafenib is administered orally as 20 or 40 mg tablets at the dose that each patient received during the last cycle of the feeder trial. The dose may be either 60, 80, 120 or 160 mg once daily for 3 weeks of every 4-week cycle (3 weeks on, 1 week off).

    Also known as: Tyrosine-kinase inhibitor

06

What researchers measure

Primary outcomes

  1. Number and Severity of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

    An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: 1. results in death 2. is life-threatening 3. requires inpatient hospitalization or prolongation of existing hospitalization, etc.

    Time frame: from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)

  2. Severity (by Worst Grade) of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

    AEs were categorized by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)

  3. Number and Severity of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs)

    A drug-related adverse event was any AE judged by investigator as having a reasonable suspected causal relationship to study drug.

    Time frame: from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)

  4. Severity (by Worst Grade) of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs)

    A drug-related adverse event was any AE judged by investigator as having a reasonable suspected causal relationship to study drug. AEs were categorized by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)

Secondary outcomes

  1. Number of Participants With Dose Modifications

    Time frame: from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)

07

Results

Posted Apr 2, 2024

Participant flow

The study was conducted in multiple centers located in 5 countries (including Germany, Japan, Italy, United Kingdom, United States), first subject first visit of the study was on 02 APR 2019 and last subject last visit was on 28 FEB 2023.

Participant flow — Overall Study
MilestoneRegorafenib
Started6
Completed0
Not completed6
Withdrew: Progressive disease1
Withdrew: Patient's decision1
Withdrew: Adverse event4

Outcome measures

PrimaryNumber and Severity of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: 1. results in death 2. is life-threatening 3. requires inpatient hospitalization or prolongation of existing hospitalization, etc.

Time frame:
from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)
Reported as:
Number · participants
Number and Severity of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
participantsRegorafenib
Any AE6
- Non-serious6
- Serious3
PrimarySeverity (by Worst Grade) of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

AEs were categorized by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Time frame:
from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)
Reported as:
Number · participants
Severity (by Worst Grade) of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
participantsRegorafenib
Worst grade - Grade 10
Worst grade - Grade 22
Worst grade - Grade 31
Worst grade - Grade 43
Worst grade - Grade 5 (death)0
PrimaryNumber and Severity of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs)

A drug-related adverse event was any AE judged by investigator as having a reasonable suspected causal relationship to study drug.

Time frame:
from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)
Reported as:
Number · participants
Number and Severity of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs)
participantsRegorafenib
Any AE5
- Non-serious5
- Serious1
PrimarySeverity (by Worst Grade) of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs)

A drug-related adverse event was any AE judged by investigator as having a reasonable suspected causal relationship to study drug. AEs were categorized by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Time frame:
from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)
Reported as:
Number · participants
Severity (by Worst Grade) of Participants With Drug-related Adverse Events (AEs) and Serious AEs (SAEs)
participantsRegorafenib
Worst grade - Grade 11
Worst grade - Grade 23
Worst grade - Grade 30
Worst grade - Grade 41
Worst grade - Grade 5 (death)0
SecondaryNumber of Participants With Dose Modifications
Time frame:
from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months)
Reported as:
Number · participants
Number of Participants With Dose Modifications
participantsRegorafenib
Any modification6
Interruption/Delay2
Drug withdrawn5

Adverse events

Collected over from the signing of the informed consent form (ICF) until the safety follow up-visit (a duration of approximately 46 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regorafenib0/6 (0%)3/6 (50%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventRegorafenib
PeritonitisInfections and infestations1/6
Electrocardiogram changeInvestigations1/6
HypocalcaemiaMetabolism and nutrition disorders1/6
HyponatraemiaMetabolism and nutrition disorders1/6
Renal failureRenal and urinary disorders1/6
DyspnoeaRespiratory, thoracic and mediastinal disorders1/6
Most frequent other events
Showing 10 of 26
Most frequent other events
EventRegorafenib
ConstipationGastrointestinal disorders2/6
HypokalaemiaMetabolism and nutrition disorders2/6
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders2/6
HypertensionVascular disorders2/6
AnaemiaBlood and lymphatic system disorders1/6
Retinal vein occlusionEye disorders1/6
Abdominal painGastrointestinal disorders1/6
Abdominal pain upperGastrointestinal disorders1/6
DiarrhoeaGastrointestinal disorders1/6
NauseaGastrointestinal disorders1/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Regorafenib
Median61 (44 to 71)
Sex: Female, Male
Sex: Female, Male(Participants)Regorafenib
Female3
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Regorafenib
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Regorafenib
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White4
More than one race0
Unknown or Not Reported0
08

Study locations

6 sites
  • Tampa General Medical Group
    Tampa, Florida 33606, United States
  • Eberhard-Karls-Universität Tübingen
    Tübingen, Baden-Württemberg 72076, Germany
  • Universitätsklinikum Köln
    Köln, Nordrhein-Westfalen 50937, Germany
  • A.O.U. Careggi
    Firenze, Toscana 50134, Italy
  • Saiseikai Utsunomiya Hospital
    Utsunomiya-shi, Tochigi 321-0974, Japan
  • Mount Vernon Hospital
    Northwood, HA6 2RN, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Feb 2023, 46 months.

Results were first posted in Apr 2024, 1 year 1 month after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 46 months is above that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2019
First posted
Mar 26, 2019
StartActual
Apr 2, 2019
Primary completionActual
Feb 28, 2023
CompletionActual
Feb 28, 2023
Results first posted
Apr 2, 2024
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03890731
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 26, 2019
Start date
Apr 2, 2019
Primary completion
Feb 28, 2023
Completion
Feb 28, 2023
Results posted
Apr 2, 2024
Last update
Apr 2, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion